Mounjaro for Teen Girls (Ages 12 to 17): What Happens When You Transition to Adult Care

Is Mounjaro Approved for Teenage Girls?

No. As of January 2025, the FDA has not approved tirzepatide (Mounjaro) for patients under 18. The approval covers adults with type 2 diabetes (Mounjaro) and adults with obesity or overweight plus a weight-related condition (Zepbound). Any use in a 12-to-17-year-old is off-label.

That does not mean it is rare. Obesity medicine specialists and pediatric endocrinologists do prescribe tirzepatide off-label for adolescents when the clinical picture justifies it, particularly when other options, including lifestyle intervention and metformin, have not produced meaningful results. The American Academy of Pediatrics 2023 Clinical Practice Guideline for the evaluation and treatment of children and adolescents with obesity acknowledges the role of intensive interventions, though tirzepatide is not named specifically because it was approved for adults after that guideline was drafted.

The clinical reality: if you are 16 or 17 and currently on tirzepatide, your prescriber is working outside labeled indications and should be monitoring you more closely than a typical adult patient.

What the Evidence Actually Shows in Adolescents

No published randomized controlled trial has yet reported tirzepatide outcomes specifically in 12-to-17-year-old females. What exists is:

• Phase 3 SURMOUNT-1 trial data in adults showing 15.0% mean body weight reduction at 72 weeks with 10 mg tirzepatide versus 3.1% with placebo, but this trial excluded anyone under 18.
• GLP-1 receptor agonist data from liraglutide trials in adolescents showing roughly 4.5% greater reduction in BMI SDS compared to placebo in the SCALE Teens trial, suggesting the GLP-1 mechanism does work in this age group.
• Extrapolated pharmacokinetic assumptions, not measured adolescent PK data for tirzepatide specifically.

This evidence gap matters. When your care team titrates your dose, they are making a clinical judgment, not following a tested adolescent protocol. Knowing this is not cause for alarm; it is a reason to stay engaged with your prescriber and report side effects carefully.

How Puberty and Your Menstrual Cycle Change the Picture

Puberty is one of the most hormonally complex periods of a woman's life. Estrogen, progesterone, luteinizing hormone, follicle-stimulating hormone, insulin, and growth hormone are all fluctuating in ways that have no adult equivalent. Tirzepatide acts on both GLP-1 and GIP receptors, and both pathways intersect with insulin signaling and ovarian function.

GLP-1, GIP, and Your Ovaries

GLP-1 receptors are expressed in ovarian granulosa cells and in the hypothalamus, where they influence gonadotropin-releasing hormone (GnRH) pulsatility. In women with polycystic ovary syndrome (PCOS), a condition that affects up to 10% of adolescent girls, GLP-1 agonists have been shown to reduce fasting insulin, lower androgen levels, and in some cases restore more regular menstrual cycles. GIP receptors are also expressed in adipose and gonadal tissue, though direct human ovarian data for the GIP pathway remains thin.

What this means practically: if you have PCOS or irregular periods and you start tirzepatide, your cycles may change. That can be a good change (more regular ovulation) or an unexpected one (return of fertility you did not anticipate). Both require attention to contraception.

Bone Density During Adolescence

Peak bone mass is largely established by age 18 to 20. Rapid weight loss at any age can reduce bone mineral density, and studies in adults on GLP-1 agonists have shown modest reductions in total hip BMD. In a teenager whose skeleton is still accumulating mineral, this is a specific concern that adult-focused data cannot fully address. Your pediatric team should document baseline bone health if rapid weight loss is anticipated, and your adult team should continue monitoring.

Nausea, Appetite Suppression, and Nutritional Adequacy

Adolescent girls are already at higher risk of disordered eating patterns and micronutrient deficiencies. Tirzepatide's dose-dependent nausea and early satiety can compound inadequate intake of calcium, iron, folate, and vitamin D during critical growth years. A registered dietitian with adolescent experience should be part of the team from the start.

The Transition: What Changes at 18 (or Whenever You Switch)

Transitions from pediatric to adult care are a documented weak point in chronic disease management. A systematic review in the Journal of Adolescent Health found that young adults who did not have a structured transition protocol were significantly more likely to lapse in care and experience worsening of their condition within the first year of transfer.

For a teen girl on tirzepatide, the transition is more complex than just switching your doctor. Here is what actually needs to transfer.

Your Medical Records and Growth Data

Your pediatric team has data that your adult provider will not automatically receive:

• Height and weight trajectory (growth charts, BMI-for-age percentiles)
• Bone age assessments if done
• Baseline and follow-up labs: fasting glucose, HbA1c, lipid panel, liver enzymes, thyroid panel
• Documentation of why tirzepatide was started off-label, what alternatives were tried, and how you responded

Request a formal transition summary. Some pediatric practices use a structured transition readiness tool; if yours does not, ask specifically for a printed or electronic summary you can carry to your first adult appointment.

Your Prescriber and Clinic Type

In pediatric settings, tirzepatide is often managed by a pediatric endocrinologist or an obesity medicine specialist within a children's hospital. As an adult, you may be transitioning to:

• An adult obesity medicine physician (board-certified in obesity medicine)
• An adult endocrinologist
• A women's health NP or PA at a telehealth platform (appropriate for stable patients without complex comorbidities)
• An OB-GYN or reproductive endocrinologist if PCOS or fertility is now a priority

The type of specialist matters. An adult internist comfortable with diabetes management may not be familiar with how tirzepatide interacts with a young woman's menstrual cycle, PCOS, or contraception needs. Be specific about what you need from your new provider.

Your Contraception Plan

This is the section that changes most between adolescent and adult care, and it is the one most often handled inadequately at transitions.

Tirzepatide is contraindicated in pregnancy. The FDA prescribing information states that women of reproductive potential should use effective contraception during treatment and for a recommended period after the last dose. The reason is that animal reproductive studies showed adverse fetal outcomes at clinically relevant exposures, and there are no adequate human data in pregnant women.

If you are 17 turning 18, and you are sexually active or plan to be, your contraception conversation belongs in this transition. Oral contraceptive pills may be absorbed less reliably during episodes of vomiting or diarrhea from tirzepatide, which means barrier methods or long-acting reversible contraception (LARC) such as an IUD or implant may offer more consistent protection.

GLP-1 agonists also slow gastric emptying, which theoretically could alter the absorption timing (though not the overall bioavailability) of oral medications including combined oral contraceptives. The clinical significance of this interaction is not yet established by direct trial data, so belt-and-suspenders contraception is a reasonable precaution while you and your provider figure out your full regimen.

Pregnancy, Lactation, and What You Need to Know Before 18 and After

This section is required reading if you are on tirzepatide and are, or might become, pregnant.

Pregnancy

Tirzepatide is classified as a reproductive risk based on animal data. Studies in rats and rabbits showed reduced fetal body weight and skeletal variations at doses producing exposures similar to those in humans at the 5 mg clinical dose. No adequate, well-controlled studies exist in pregnant women, and there is no human safety registry with sufficient numbers to draw conclusions.

The clinical instruction is plain: stop tirzepatide before attempting conception. If you become pregnant while on tirzepatide, discontinue immediately and contact your prescriber.

Eli Lilly maintains a pregnancy exposure registry for tirzepatide. If you become pregnant while taking Mounjaro or Zepbound, you or your provider can enroll at 1-800-545-5979. Registry data are critical for eventually understanding real-world pregnancy outcomes, and enrollment takes less than 10 minutes.

Lactation

There are no human data on tirzepatide transfer into breast milk, and no data on effects in a nursing infant or on milk production. Because of the unknown risk to a nursing infant and the availability of other options for weight management postpartum, tirzepatide should not be used during breastfeeding. If you are 18 or older and postpartum, discuss the timing of restarting with your provider after you have finished breastfeeding.

For Girls Under 18 Who Are Sexually Active

If you are 12 to 17, on tirzepatide off-label, and sexually active, your pediatric provider has an obligation to address contraception. This is not optional. The drug's reproductive risk does not wait until your 18th birthday. If your current prescriber has not raised this, raise it yourself.

PCOS, Insulin Resistance, and Why This Drug Affects Teen Girls Differently

PCOS is the most common endocrine disorder in reproductive-age women, affecting between 6% and 12% of women of reproductive age in the United States. It often first appears in adolescence, and insulin resistance is central to its pathophysiology in the majority of cases.

For a teen girl with PCOS and obesity, tirzepatide addresses two interconnected problems at once: it reduces body weight and it directly improves insulin sensitivity through both the GLP-1 and GIP pathways. Adult trials in women with PCOS using semaglutide (a GLP-1-only agonist) have shown improvements in menstrual regularity, androgen levels, and metabolic markers, with one 2023 randomized trial in Fertility and Sterility reporting restoration of regular cycles in 63% of women with PCOS and obesity after 24 weeks. Tirzepatide's dual mechanism may produce similar or greater benefit, but direct PCOS-specific trial data for tirzepatide in adolescent girls does not yet exist.

What you should track: cycle length and regularity (an app is fine), any new acne or hair changes, and any symptoms of hypoglycemia, which is uncommon in non-diabetic patients but possible if caloric intake drops sharply.

Who This Is Right For (and Who It Is Not)

Not every teen girl should be on tirzepatide, and the transition to adult care is a good moment to re-evaluate whether this remains the right tool for you.

More Likely to Benefit

• Girls 12 to 17 with clinically severe obesity (BMI at or above the 120% of the 95th percentile threshold, or BMI above 35 with a weight-related comorbidity), who have not responded to at least 3 to 6 months of structured lifestyle intervention
• Those with PCOS, prediabetes, or non-alcoholic fatty liver disease where metabolic benefit extends beyond weight alone
• Patients who tolerated the titration well and achieved meaningful response (5% or greater body weight reduction within 12 weeks of effective dose)

Less Likely to Benefit or Should Not Use

• Anyone who is pregnant or planning conception in the near term
• Girls with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN 2), because tirzepatide carries an FDA black-box warning for thyroid C-cell tumors based on rodent data; the human relevance is uncertain but the contraindication stands
• Those with active or recently treated eating disorders, because appetite-suppressing medication in this context requires close psychiatric coordination
• Anyone with gastroparesis or severe gastrointestinal dysmotility
• Girls whose weight trajectory has naturally stabilized post-puberty and who no longer meet the metabolic criteria for treatment

Practical Checklist for the Transition Appointment

Before you leave pediatric care, make sure the following are in hand or formally arranged.

1. Written transition summary including diagnoses, dates of treatment start, dose history, lab trends, and the reason tirzepatide was chosen.
2. A 90-day supply or a confirmed prescription transfer to your new provider, so there is no gap in access.
3. Contraception plan documented in the chart, not just discussed verbally.
4. Referral to a registered dietitian if you are not already working with one.
5. A scheduled first adult-care appointment before your last pediatric appointment. Do not leave without a date.
6. Your personal records: growth charts, bone density if done, and any imaging (ultrasound for PCOS if applicable).

Your new adult provider should do a full metabolic panel, thyroid function test, and HbA1c within the first 90 days of taking over your care. If they suggest stopping tirzepatide without a clinical reason, ask for a formal review of your records before agreeing. Weight regain after discontinuation is well-documented. One analysis of the SURMOUNT-1 extension showed participants who discontinued tirzepatide regained approximately two-thirds of their lost weight within one year, underscoring that this is a chronic treatment, not a short course.

Monitoring That Belongs in Every Follow-Up

Whether you are 17 with a pediatric endocrinologist or 19 with a telehealth NP, the monitoring schedule for tirzepatide should include the following.

| What to Monitor | Frequency | |---|---| | Body weight and BMI | Every 4 weeks during titration, then every 3 months | | Fasting glucose and HbA1c | Every 3 to 6 months | | Lipid panel | Every 6 to 12 months | | Liver enzymes (AST/ALT) | Every 6 months | | Thyroid function (TSH) | Annually | | Menstrual cycle regularity | Every visit (patient-reported) | | Bone health (DXA if indicated) | At baseline if rapid weight loss; repeat per provider judgment | | Contraception review | Every visit | | Nutritional labs (ferritin, folate, vitamin D, B12) | Annually or if symptomatic |

Side effects that should prompt same-week contact with your provider: persistent vomiting lasting more than 48 hours, severe abdominal pain radiating to the back (possible pancreatitis), vision changes, racing heart, or any pregnancy symptoms.

The Evidence Gap We Are Still Filling

To be direct: the data on tirzepatide in adolescent girls specifically is thin. The drug is newer than semaglutide. The adolescent obesity trials that exist for GLP-1 agonists used liraglutide and semaglutide, not tirzepatide. SURMOUNT-1 enrolled adults only. SURMOUNT-2 enrolled adults with type 2 diabetes only. Pediatric tirzepatide trials are in planning or early enrollment phases as of this writing, but no results have been published.

What this means for you: your experience is genuinely contributing to the evidence base. Report side effects through your provider and, if you experience any serious adverse event, through the FDA MedWatch system. Registry participation matters.

As Eli Lilly's clinical development team continues adolescent studies, guidelines will follow. The transition checkpoint at 18 may eventually be replaced by age-appropriate dosing protocols with their own titration schedules. We do not have that yet. For now, the 2.5 mg to 15 mg adult titration schedule is what your prescriber has to work with.